327 Clinical outcome and therapeutic strategies in non proband children with genetically confirmed LQTS

A. Brondex, Vincent Probst(Centre National de la Recherche Scientifique), Philippe Mabo, Frédéric Sacher(Centre Hospitalier Universitaire de Bordeaux), Bertrand Petit, Hervé Le Marec(Centre National de la Recherche Scientifique), Laurence Jesel(Université de Strasbourg), Jacques Mansourati(Université de Bretagne Occidentale)
Archives of Cardiovascular Diseases Supplements
January 1, 2012
10.1016/s1878-6480(12)70723-1
Cited by 0

Related Papers

HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies
|Heart Rhythm|2011|1.5k
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death
|Nature|2003|961
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)
|EP Europace|2011|904
Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome
|Circulation|2010|850
Cardiac conduction defects associate with mutations in SCN5A
|Nature Genetics|1999|638